Even though the mechanism of action of TIM3 thus remains unresolved, its preferential expression on CD8+ TIL makes it an attractive candidate for a direct regulator of the interaction between CTL and their tumor target cells. The gene discussed is HAVCR2; the disease is neoplasm.